why choose us

First received: September 24, 2026

Clinical Trial: Real-World Incidence of Intraocular Inflammation Following Intravitreal Treatment With Aflibercept 8 mg

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Intraocular Inflammation
Intravitreal Injections

Study Type: OBSERVATIONAL


Official Title: Real-World Incidence of Intraocular Inflammation Following Intravitreal Treatment With Aflibercept 8 mg

Brief Summary: Aflibercept 8 mg is a high-concentration anti-vascular endothelial growth factor therapy developed to extend treatment intervals for retinal diseases while maintaining the efficacy and safety of aflibercept 2 mg. Phase 3 trials supported its use in neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.The aim of this study was to estimate the incidence of intraocular inflammation (IOI) after intravitreal aflibercept 8 mg injections in an unselected cohort treated at a…

Read more